Lifetech Scientific Corporation (HKG: 1302) announced that the ICS Elpis Bioresorbable Peripheral Balloon‑Expandable Covered Stent System, independently developed by its subsidiary Yuanxin Technology (Shenzhen) Co., Ltd., was approved for entry into the Special Review Procedure for Innovative Medical Devices of China’s National Medical Products Administration (NMPA) — the national innovative medical device “Green Channel” — marking the world’s first fully bioresorbable peripheral covered stent system to reach this priority regulatory pathway.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Pathway | Special Review Procedure for Innovative Medical Devices (“Green Channel”) |
| Product | ICS Elpis Bioresorbable Peripheral Balloon‑Expandable Covered Stent System |
| Indication | Atherosclerotic stenosis or occlusion of the common iliac artery and external iliac artery |
| Entry Date | 19 Oct 2026 |
| Platform Milestone | 4th product from Lifetech’s iron‑based bioresorbable material platform to enter the Green Channel |
| Company Milestone | 20th Lifetech innovative product admitted to the Green Channel |
| Next Steps | Pivotal clinical evaluation and registration review under the priority pathway; timeline not disclosed |
Product Profile & Mechanism of Action
- Product Class: Bioresorbable peripheral balloon‑expandable covered stent system — combining a bioresorbable scaffold with a covered (sealed) design for peripheral arterial intervention.
- World‑First Positioning: Billed as the world’s first fully bioresorbable peripheral covered stent system, extending resorbable scaffold concepts beyond coronary applications into the peripheral vasculature.
- Target Lesions: Atherosclerotic stenosis or occlusion of the common iliac artery and external iliac artery, large‑vessel segments feeding the lower extremities.
- Material Platform: Built on Lifetech’s proprietary iron‑based bioresorbable material platform — the fourth ICS Elpis‑family entry from this technology base to win Green Channel admission.
- Bioresorbable Advantage: Full resorption is designed to restore native vessel physiology after scaffold support is no longer needed, avoiding the permanent metallic implant burden associated with conventional covered stents — a differentiator for younger patients and long vessel segments.
- Delivery: Balloon‑expandable architecture enables precise deployment in iliac anatomy.
Clinical Evidence – First‑in‑Human (FIM) Study
| Endpoint | Result |
|---|---|
| Enrollment Status | All subjects enrolled (study complete enrollment) |
| Device Success Rate | 100 % |
| Procedure Success Rate | 100 % |
| Vessel Patency | Target vessels remained patent immediately post‑procedure and during follow‑up |
The first‑in‑human study of ICS Elpis has completed enrollment of all subjects, with results demonstrating 100 % device success and 100 % procedure success rates, and sustained vessel patency from immediately after implantation through follow‑up. Additional endpoints, follow‑up duration, and pivotal trial design details were not disclosed.
Market Impact & Outlook
- Peripheral Intervention Landscape: Iliac artery disease represents a substantial segment of peripheral artery disease intervention, where conventional balloon‑expandable covered stents are permanent implants — a fully bioresorbable alternative addresses an unmet need for vessel restoration after healing.
- Green Channel Advantage: NMPA’s Special Review Procedure grants priority review and earlier regulatory interaction, potentially accelerating ICS Elpis toward market relative to standard‑pathway Class III devices.
- Platform Validation: As the fourth iron‑based bioresorbable platform product to enter the Green Channel — and Lifetech’s 20th overall — ICS Elpis reinforces Lifetech Scientific’s position as one of China’s most prolific innovative medical device developers, with a resorbable‑materials franchise spanning vascular and structural heart portfolios.
- Competitive Edge: No directly comparable fully bioresorbable peripheral covered stent system has been identified to date, giving ICS Elpis first‑mover positioning in the category globally.
- Disclosures: Pivotal trial timing, commercial forecasts, and registration submission plans were not disclosed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, regulatory review, and commercial expectations for the ICS Elpis Bioresorbable Peripheral Balloon‑Expandable Covered Stent System. Actual results may differ materially due to risks including pivotal trial outcomes, NMPA review timelines and requirements, market adoption, and competitive dynamics. Green Channel admission does not guarantee eventual marketing approval.-Fineline Info & Tech
